Drug profile

The FDA adverse-event record for Clostridium Chauvoei + Clostridium Novyi + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii

13 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Clostridium Chauvoei + Clostridium Novyi + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii. See the species affected, top reactions, and outcomes below.

13
adverse-event reports
92.3%
death-coded share
Cattle
most-reported species
12
Death - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
12
Deaths Reported
92.3%
Death Rate

Active Ingredients

Clostridium ChauvoeiClostridium NovyiClostridium Perfringens Type C Bacterin ToxoidClostridium Perfringens Type D Bacterin ToxoidClostridium SepticumClostridium Sordellii

Administration Routes

SubcutaneousUnknown

Species Affected

Cattle 12
Bison 1

Most Affected Breeds

Cattle (other) 7
Aberdeen Angus 3
American bison 1
Crossbred Bovine/Cattle 1
Cattle (unknown) 1

Most Reported Reactions

Death 12
Lack of efficacy - NOS 4
Lack of efficacy (bacteria) - NOS 4
Respiratory signs 2
Lack of efficacy (virus) - NOS 2
Unclassifiable adverse event 2
NT - Abnormal necropsy finding NOS 2
INEFFECTIVE, ANTIBIOTIC 1
Neurological signs NOS 1
Myopathy 1
Haemothorax 1
Other abnormal test result NOS 1

Outcome Breakdown

Died
12 (54.5%)
Outcome Unknown
4 (18.2%)
Recovered/Normal
3 (13.6%)
Ongoing
2 (9.1%)
Euthanized
1 (4.5%)

Clostridium Chauvoei + Clostridium Novyi + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii Adverse Event Insights

13 reports name Clostridium Chauvoei + Clostridium Novyi + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii; 12 recorded a death outcome (92.3% of reported events, not a population-level mortality rate). Active ingredients: Clostridium Chauvoei, Clostridium Novyi, Clostridium Perfringens Type C Bacterin Toxoid, Clostridium Perfringens Type D Bacterin Toxoid, Clostridium Septicum. Administration routes: Subcutaneous, Unknown.

By species: Cattle (12 reports), Bison (1 reports). By breed: Cattle (other) (7), Aberdeen Angus (3), American bison (1).

Leading clinical signs: Death (12), Lack of efficacy - NOS (4), Lack of efficacy (bacteria) - NOS (4), Respiratory signs (2). Outcome, 22 coded reports: Died leads at 54.5%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.